You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

February 22, 2018

First Official Guidelines on Food Recall in Indonesia

Informed Counsel

The Indonesia National Agency of Drug and Food Control (NADFC) has issued the nation’s first official guidelines for food recall in the Head of NADFC Regulation No. 22 of 2017, which entered into force on November 28, 2017. The regulation establishes food recall procedures for manufacturers, importers, and distributors who are obligated to recall food products that are not in accordance with requirements set forth in prevailing laws and regulations.

Food recall is applicable to registered and unregistered processed food products, both local and imported. These include exported food products that have problems in the designated exporting country, and domestic processed food products registered with Indonesian municipal government authorities.

Mandatory Recall

Mandatory food recall requires an order from the NADFC, and may occur if a distributed product poses risk of causing disease or injury; a product does not meet food safety laws or regulations; or the recall is deemed necessary to protect public health.

The NADFC may utilize information from the following sources to determine whether to order a mandatory product recall:

  1. Balai Besar/Balai POM (i.e., provincial-level authority of NADFC);
  2. Nongovernmental organizations;
  3. Research institutions or universities;
  4. Mass media;
  5. Consumers;
  6. Food business operators;
  7. Overseas and international food safety organizations (e.g., International Food Safety Authorities Network, the European Union Rapid Alert System for Food and Fee, etc.); and
  8. Other official sources.

Voluntary Recall

A food business operator such as a manufacturer, importer, distributor, or retailer, may use information from the following sources to determine whether to conduct voluntary recall of a food product:

  1. Test data;
  2. Consumers;
  3. Supplier of food ingredient used by a manufacturer;
  4. Federal and provincial government agencies; and
  5. Other sources.

The manufacturer, importer, or distributor must provide the following information to the NADFC in order to conduct a voluntary recall:

  1. Identity of food product to be recalled;
  2. Reason for recall;
  3. Risk assessment of shortage of product supply in the market;
  4. Quantity of food produced or being produced;
  5. Quantity of food estimated to be in distribution;
  6. Distribution information, including contact persons’ details if necessary;
  7. Records of communication related to the food recall;
  8. Plan/strategy for food recall; and
  9. Contact details of responsible persons at the company conducting the food recall.

The intent to recall a food product must be communicated to the NADFC through its 24-hour call center, and to buyers and consumers through letters, emails, or fax.

Recall Classifications

Based on information received, the NADFC will conduct a health risk assessment to determine the classification of the food recall, with three classification types:

Class I recall. To qualify as a Class I recall, consumption of or exposure to the food product is presumed to cause serious health problems or even death. The timeline for a Class I Recall is as follows:

  • Issuance of a public warning by the NADFC within 24 hours after determination of the  classification of the recall;
  • Recalled products are prohibited for sale or purchase and must be secured immediately after the public warning;
  • Food products to be recalled must be cleared from markets within 14 calendar days after issuance of the NADFC’s recall order.

Class II recall. In a Class II recall, consumption of or exposure to the food product is presumed to cause temporary disruption to health, recoverable disruption to health, or a small possibility of serious disruption to health. This classification includes food that does not meet the mandatory Indonesian National Standard for quality, packaged food products that are distributed without a marketing permit, and food products that contain pork but fail to disclose this information on their food label. Food products to be recalled under Class II must be cleared from markets within 30 calendar days of issuance of the NADFC’s recall order.

Class III recall. In a Class III recall, consumption of or exposure to a food product is not detrimental to health, but there is a breach of regulation other than those mentioned under Class I and II recalls. Food products to be recalled under Class III must be cleared from markets within 60 calendar days of issuance of the NADFC’s recall order.

Recall Procedure

The process for a food recall in Indonesia consists of several steps. First, the NADFC will issue a recall order to the food manufacturer or importer after completing its health risk assessment. The NADFC will then issue a circular to all Balai Besar/Balai POM to instruct them to coordinate with local government agencies in the recall. In the case of a Class I recall, the circular will also include instructions to secure and destroy food products.

A public warning is subsequently issued by NADFC in a Class I recall, or by the relevant business operator in a voluntary recall. The recall is then executed within the provided timeline and recalled products are handled in accordance with official guidelines. If the recall has been effectively executed, the NADFC will issue an order letter to cease the recall; otherwise, an order letter to repeat the recall will be issued.

The NADFC will determine the next course of action on the recalled products for products in mandatory recalls, while products in voluntary recalls may be handled in the following ways as determined by the company: destroyed; used for other purposes besides human consumption (e.g., as animal feed); reprocessed to ensure food safety; relabeled; or returned to suppliers (in the case of imported food products).

Reporting

All activities related to a food recall must be documented and reported to the NADFC by the manufacturer, importer, or distributor. There are two types of reports:

A progress report must be provided to confirm that the responsible party has identified all products to be recalled, and has communicated about the recall to all related parties. The progress report must be provided within 10 working days from the start of a Class II or III recall. For a Class I recall, the NADFC will determine the timeline for providing a progress report.

A final report must be provided within 10 working days after the recall is completed. It will be used by the NADFC to assess the effectiveness of the recall process.

Simulation Exercise

As part of food recall guidelines, business operators are required to perform a food recall and food traceability simulation exercise at least once a year, and document the exercise activities and results. This requirement is intended to measure the effectiveness of current food recall and food traceability systems.

The guidelines set forth in the Head of NADFC Regulation No. 22 of 2017 appear to provide a comprehensive framework for business operators to follow when a recall is deemed necessary. Although the guidelines are still relatively new, it is hoped that they will contributed to more effective food recalls and promote the confidence of food and beverage investors in Indonesia.

RELATED INSIGHTS​ 

July 1, 2026
Obtaining marketing authorization is a fundamental requirement for bringing pharmaceutical products to the Thai market. Companies must navigate the Thai Food and Drug Administration’s registration procedures while also complying with post-approval pharmacovigilance obligations, licensing requirements for manufacturing and importation, data protection rules, and other regulatory requirements. This guide provides an overview of Thailand’s regulatory framework for pharmaceutical marketing authorization, including available registration pathways, review timelines, application fees, postmarketing surveillance obligations, licensing requirements, exemptions, data exclusivity, freedom of information, and parallel import considerations. It is intended as a practical reference for pharmaceutical companies, regulatory affairs professionals, and others involved in bringing medicinal products to the Thai market. Download the guide below for a concise overview of the current requirements and procedures governing pharmaceutical marketing authorization in Thailand.
June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements
June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU